Back to Companies
Contineum Therapeutics, Inc.
CTNMNasdaqCIK: 0001855175
Over the 27 most recent insider filings, Contineum Therapeutics, Inc. (CTNM) has seen activity from 11 distinct insiders — all of them on the sell side. The activity is heavily weighted toward selling: $0 bought versus $1.7M sold, net sales of $1.7M. Stengone Carmine N. (CEO and President, Director) is the most active by dollar volume, and the single largest transaction was $6.3M by Stengone Carmine N.. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.
Total Volume
$17.6M
Purchases
$0
Sales
$1.7M
Unique Insiders
11
Recent Insider Trades
27 loaded
| Jul 8 | CTNM Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO and President, Director | Sell | $40.0K |
| Jul 10 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $16.6K |
| Jul 1 | CTNM Contineum Therapeutics, Inc. | Watkins Tim | CMO & Head of Development | Sell | $173.6K |
| Jul 2 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $594.6K |
| Jul 1 | CTNM Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO and President, Director | Sell | $160.1K |
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Ignelzi Troy A. | Director | Award | $269.6K |
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Boyce Sarah | Director | Award | $269.6K |
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Brady Todd R. | Director | Award | $269.6K |
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Miralles Gines Diego | Director | Award | $269.6K |
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Lyons-Williams Lori | Director | Award | $269.6K |
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Schimmelpennink Evert B. | Director | Award | $269.6K |
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Ware Olivia C | Director | Award | $269.6K |
| Jun 1 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $54.9K |
| May 1 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $54.7K |
| Apr 6 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $56.0K |
| Mar 2 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $62.6K |
| Mar 2 | CTNM Contineum Therapeutics, Inc. | Watkins Tim | CMO & Head of Development | Sell | $54.2K |
| Feb 26 | CTNM Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO and President, Director | Sell | $113.7K |
| Feb 26 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $130.2K |
| Feb 20 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $1.6K |
| Feb 13 | CTNM Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO and President, Director | Sell | $6.4K |
| Jan 30 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Award | $2.4M |
| Jan 30 | CTNM Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO and President, Director | Award | $6.3M |
| Jan 30 | CTNM Contineum Therapeutics, Inc. | Slover Peter T | Chief Financial Officer | Award | $2.7M |
| Jan 30 | CTNM Contineum Therapeutics, Inc. | Watkins Tim | CMO & Head of Development | Sell | $51.2K |
| Jan 6 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $43.5K |
| Dec 30 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | $51.0K |
27 filings